Shattuck is a biotechnology company developing a potentially first-in-class antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck's expertise in protein engineering and commitment to pursuing the development of novel therapeutics targeting TNF receptors come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve complete and more durable blockade of the clinically validated TL1A/DR3 pathway. Shattuck intends to file an Investigational New Drug application (IND) for SL-325 in the third quarter of 2025.